Immunovant Inc (Immunovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops antibodies for the treatment of autoimmune diseases. The company’s pipeline products include batoclimab and MVT-1402. Its batoclimab treats myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and graves disease. It is also evaluating its IMVT-1402, for the treatment of autoimmune disease. The company seeks to collaborate with HanAll Biopharma Co Ltd for the research and development of next-generation FcRn inhibitors. The company operates in Switzerland, Bermuda and the US. Immunovant is headquartered in New York, the US.
Immunovant Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Batoclimab: Myasthenia Gravis, Thyroid Eye Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Graves Disease |
IMVT-1402: Autoimmune Disease |
Competitor Comparison
Key Parameters | Immunovant Inc | Alexion Pharmaceuticals Inc | Argenx SE | Hyliion Holdings Corp | Momenta Pharmaceuticals Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Netherlands | United States of America | United States of America |
City | New York | Boston | Amsterdam | Cedar Park | Cambridge |
State/Province | New York | Massachusetts | Noord-Holland | Texas | Massachusetts |
No. of Employees | 164 | 3,000 | 1,148 | 85 | - |
Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Frank Torti, M.D. | Chairman | Executive Board | 2021 | 44 |
Peter Salzmann, M.D. | Chief Executive Officer | Senior Management | 2019 | 55 |
Renee Barnett | Chief Financial Officer | Senior Management | 2021 | 43 |
Jay S. Stout | Chief Technology Officer | Senior Management | 2020 | - |
Mark S. Levine | Chief Legal Officer; Secretary | Senior Management | 2022 | 49 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer